Browse Studies — Arctuva

Phase 1

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer th…

Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05950464

Phase 2

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismat…

Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+6 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05112601

A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancer

This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in pat…

Endometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Mucinous Adenocarcinoma+3 more

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT05049538

Phase 3

Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachyther…

Endometrial Clear Cell AdenocarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Serous Adenocarcinoma+6 more

Estimated

~$10 – $6,250

University of UtahNCT03422198